FilingReader Intelligence
Zhejiang Xianju gets drug application accepted for review
July 11, 2025 at 08:02 AM UTC•By FilingReader AI
Zhejiang Xianju Pharmaceutical received notification from the National Medical Products Administration regarding acceptance of its application for domestic production of Tiotropium Bromide Inhalation Spray.
The product is designed for chronic obstructive pulmonary disease treatment, including chronic bronchitis and emphysema. The formulation matches reference drug Spiriva Respimat by Boehringer Ingelheim International.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002332•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Xianju Pharmaceutical publishes news
Free account required • Unsubscribe anytime